ImpediMed

ImpediMed EBITDA Growth YoY

The Year-over-Year EBITDA Growth of ImpediMed (IPD.AX) as of Nov 12, 2026 is -14.15 %. In the previous year, Year-over-Year EBITDA Growth was -17.18 % — a change of -17.65% (higher).

EBITDA Growth YoY

-14.15 %

YoY

-17.65%

Last updated:

Year-over-Year EBITDA Growth of ImpediMed is 2026 -14.15 % . Year-over-Year EBITDA Growth of ImpediMed was 2025 -17.18 % . It decreases by -17.65% higher compared to the previous year.

The ImpediMed EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2019
13.26 AUD
Jan 1, 2020
8.39 AUD
Jan 1, 2021
11.45 AUD
Jan 1, 2022
13.41 AUD
Jan 1, 2023
-10.41 AUD
Jan 1, 2024
17.65 AUD
Jan 1, 2025
-17.18 AUD
Jan 1, 2026
-14.15 AUD
The ImpediMed EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-14.15 %-17.65%
-17.18 %-197.38%
17.65 %-269.55%
-10.41 %-177.60%
13.41 %+17.11%
11.45 %+36.54%
8.39 %-36.75%
13.26 %+1,659.78%
0.75 %-109.65%
-7.81 %-91.21%
-88.80 %-1.12%
-89.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Year-over-Year EBITDA Growth of ImpediMed is -14.15 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth ImpediMed since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ImpediMed

All Key Metrics — ImpediMed